Neuroblastoma

신경모세포종

  • Kang, Hyoung-Jin (Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine) ;
  • Ryu, Kyung-Ha (Department of Pediatrics, Ewha Womans University College of Medicine) ;
  • Shin, Hee-Young (Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine) ;
  • Ahn, Hyo-Seop (Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine)
  • 강형진 (서울대학교 의과대학 소아과학교실, 암연구소) ;
  • 유경하 (이화여자대학교 의과대학 소아과학교실) ;
  • 신희영 (서울대학교 의과대학 소아과학교실, 암연구소) ;
  • 안효섭 (서울대학교 의과대학 소아과학교실, 암연구소)
  • Received : 2008.05.23
  • Published : 2008.06.30

Abstract

Neuroblastoma arises from the primitive neural crest cells, and is a common malignancy in childhood. The clinical features are characterized by biological heterogeneity. Neuronal degeneration and differentiation occur in some patients. However treatment in the high risk group accounting for approximately half, has not been satisfactory despite a multimodal approach. Therefore, effective treatment is determined by the risk group of prognostic factors, such as age at diagnosis, stage of disease, pathological finding and N-myc amplification. Neuroblastoma can be diagnosed prenatally, which suggests its origin during the normal embryogenesis. Recent knowledge of molecular biology, such as Trk genes, and the concept of cancer stem cells have given us some improved understanding on this disease. Currently, targeted therapies based on the molecular biology of neuroblastoma are under investigation and increasing survival rate and decreasing late complications could be appreciated.

Keywords